DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4 + T cells, but few subdominant epitope-specific CD8 + T cells

Vaccine

Volumn 29, Issue 43, 2011, Pages 7483-7490

  Vojnov, Lara ^a   Bean, Alexander T ^a   Peterson, Eric J ^b   Chiuchiolo, Maria J ^c   Sacha, Jonah B ^a   Denes, Ferencz S ^d   Sandor, Matyas ^a   Fuller, Deborah H ^e,f   Fuller, James T ^f   Parks, Christopher L ^c   McDermott, Adrian B ^c   Wilson, Nancy A ^a   Watkins, David I ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CD4+ T cells; CD8+ T cells; DNA Ad5 vaccination; Subdominant epitopes

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EPITOPE; GAG PROTEIN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEF PROTEIN; REV PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA IMMUNIZATION; ELECTROPORATION; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNODOMINANT EPITOPES; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, DNA; VIRAL PROTEINS;

EID: 80053442304     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.048     Document Type: Article

References (67)

1. Chen W., Antón L.C., Bennink J.R., Yewdell J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000, 12:83-93.
2. Chen Z.W., Craiu A., Shen L., Kuroda M.J., Iroku U.C., Watkins D.I., et al. Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J Immunol 2000, 164:6474-6479.
3. Gallimore A., Dumrese T., Hengartner H., Zinkernagel R.M., Rammensee H.G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998, 187:1647-1657.
4. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002, 168:4391-4398.
5. Rodriguez F., Harkins S., Slifka M.K., Whitton J.L. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 2002, 76:4251-4259.
6. Altfeld M., Rosenberg E.S. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 2000, 12:375-380.
7. Bevan M.J. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004, 4:595-602.
8. Kalams S.A., Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998, 188:2199-2204.
9. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994, 68:8056-8063.
10. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002, 169:6376-6385.
11. Friedrich T.C., Valentine L.E., Yant L.J., Rakasz E.G., Piaskowski S.M., Furlott J.R., et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007, 81:3465-3476.
12. Giraldo-Vela J.P., Bean A.T., Rudersdorf R., Wallace L.T., Loffredo J.T., Erickson P., et al. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics 2010, 62:701-707.
13. Giraldo-Vela J.P., Rudersdorf R., Chung C., Qi Y., Wallace L.T., Bimber B., et al. The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J Virol 2008, 82:859-870.
14. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
15. Wilson N.A., Keele B.F., Reed J.S., Piaskowski S.M., MacNair C.E., Bett A.J., et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009, 83:6508-6521.
16. Chea S., Dale C.J., De Rose R., Ramshaw I.A., Kent S.J. Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol 2005, 79:3748-3757.
17. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10:1359-1365.
18. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003, 9:27-32.
19. Fuller D.H., Shipley T., Allen T.M., Fuller J.T., Wu M.S., Horton H., et al. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology 2007, 364:245-255.
20. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173:3148-3154.
21. Fifis T., Mottram P., Bogdanoska V., Hanley J., Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004, 23:258-266.
22. Minigo G., Scholzen A., Tang C.K., Hanley J.C., Kalkanidis M., Pietersz G.A., et al. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine 2007, 25:1316-1327.
23. Schreiber H.A., Prechl J., Jiang H., Zozulya A., Fabry Z., Denes F., et al. Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells. J Immunol Methods 2010, 356:47-59.
24. Kalkanidis M., Pietersz G.A., Xiang S.D., Mottram P.L., Crimeen-Irwin B., Ardipradja K., et al. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods 2006, 40:20-29.
25. Scheerlinck J.P., Gloster S., Gamvrellis A., Mottram P.L., Plebanski M. Systemic immune responses in sheep, induced by a novel nano-bead adjuvant. Vaccine 2006, 24:1124-1131.
26. Kaizu M., Borchardt G.J., Glidden C.E., Fisk D.L., Loffredo J.T., Watkins D.I., et al. Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 2007, 59:693-703.
27. Loffredo J.T., Maxwell J., Qi Y., Glidden C.E., Borchardt G.J., Soma T., et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 2007, 81:8827-8832.
28. Ignatius R., Tenner-Racz K., Messmer D., Gettie A., Blanchard J., Luckay A., et al. Increased macrophage infection upon subcutaneous inoculation of rhesus macaques with simian immunodeficiency virus-loaded dendritic cells or T cells but not with cell-free virus. J Virol 2002, 76:9787-9797.
29. Obermaier B., Dauer M., Herten J., Schad K., Endres S., Eigler A. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online 2003, 5:197-203.
30. Pertmer T.M., Eisenbraun M.D., McCabe D., Prayaga S.K., Fuller D.H., Haynes J.R. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995, 13:1427-1430.
31. Denes F., Manolache S., Ma Y., Shamamian V., Ravel B., Prokes S. Dense medium plasma synthesis of carbon/iron-based magnetic nanoparticle system. J Appl Phys 2003, 94:3498-3508.
32. Kulkarni V., Jalah R., Ganneru B., Bergamaschi C., Alicea C., von Gegerfelt A., et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 2010, 10.1016/j.vaccine.2010.12.056.
33. Valentin A., Chikhlikar P., Patel V., Rosati M., Maciel M., Chang K.H., et al. Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009, 27:4840-4849.
34. Cristillo A.D., Weiss D., Hudacik L., Restrepo S., Galmin L., Suschak J., et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 2008, 366:29-35.
35. Dolter K.E., Evans C.F., Ellefsen B., Song J., Boente-Carrera M., Vittorino R., et al. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 2011, 29:795-803.
36. Luxembourg A., Hannaman D., Ellefsen B., Nakamura G., Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 2006, 24:4490-4493.
37. Boyer J.D., Robinson T.M., Kutzler M.A., Parkinson R., Calarota S.A., Sidhu M.K., et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005, 34:262-270.
38. Anderson R.D., Haskell R.E., Xia H., Roessler B.J., Davidson B.L. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000, 7:1034-1038.
39. Loffredo J.T., Sidney J., Wojewoda C., Dodds E., Reynolds M.R., Napoé G., et al. Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J Immunol 2004, 173:5064-5076.
40. Allen T.M., Mothé B.R., Sidney J., Jing P., Dzuris J.L., Liebl M.E., et al. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol 2001, 75:738-749.
41. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80:5875-5885.
42. Yewdell J.W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006, 25:533-543.
43. Friedrich T.C., Dodds E.J., Yant L.J., Vojnov L., Rudersdorf R., Cullen C., et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004, 10:275-281.
44. Mothé B.R., Horton H., Carter D.K., Allen T.M., Liebl M.E., Skinner P., et al. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol 2002, 76:875-884.
45. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26:3112-3120.
46. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81:5257-5269.
47. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22:2489-2493.
48. Otten G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006, 24:4503-4509.
49. Rosati M., von Gegerfelt A., Roth P., Alicea C., Valentin A., Robert-Guroff M., et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005, 79:8480-8492.
50. Schadeck E.B., Sidhu M., Egan M.A., Chong S.Y., Piacente P., Masood A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24:4677-4687.
51. Winstone N., Wilson A.J., Morrow G., Boggiano C., Chiuchiolo M.J., Lopez M., et al. Enhanced control of pathogenic SIVmac239 replication in macaques immunized with a plasmid IL12 and a DNA prime, viral vector boost vaccine regimen. J Virol 2011.
52. Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008, 26:4819-4829.
53. Zhang L., Nolan E., Kreitschitz S., Rabussay D.P. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta 2002, 1572:1-9.
54. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
55. Veazey R.S., Tham I.C., Mansfield K.G., DeMaria M., Forand A.E., Shvetz D.E., et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol 2000, 74:57-64.
56. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
57. Li Q., Duan L., Estes J.D., Ma Z.M., Rourke T., Wang Y., et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
58. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
59. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
60. Brenchley J.M., Ruff L.E., Casazza J.P., Koup R.A., Price D.A., Douek D.C. Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 2006, 80:6801-6809.
61. Le Gall S., Stamegna P., Walker B.D. Portable flanking sequences modulate CTL epitope processing. J Clin Invest 2007, 117:3563-3575.
62. Yewdell J.W. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 2005, 207:8-18.
63. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53.
64. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
65. Loffredo J.T., Bean A.T., Beal D.R., León E.J., May G.E., Piaskowski S.M., et al. Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication. J Virol 2008, 82:1723-1738.
66. Martins M.A., Wilson N.A., Reed J.S., Ahn C.D., Klimentidis Y.C., Allison D.B., et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 2010, 84:4352-4365.
67. Manuel E.R., Charini W.A., Sen P., Peyerl F.W., Kuroda M.J., Schmitz J.E., et al. Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses. J Virol 2006, 80:12032-12040.